iSpecimen Inc. CEO Transition — Shahin Behroyan Appointed

What Happened

• iSpecimen Inc. announced on August 26, 2026 that Katharyn Field will transition from her role as Chief Executive Officer and will continue to support the company in an internal advisory and consulting capacity. The Board appointed Shahin Behroyan as Chief Executive Officer effective immediately. The filing states Ms. Field’s departure was not due to any disagreement with the company’s operations, policies, or practices.

Key Details

• Appointment effective: August 26, 2026; incoming CEO: Shahin Behroyan (age 39).
• Compensation structure: Behroyan will serve as an independent contractor through 1605811 BC Ltd.; annual fee of $350,000, paid monthly ($29,166.67/month); no employee benefits.
• Termination and severance: Agreement may be terminated by the Board at any time, with or without notice or cause; if terminated without cause (or if Behroyan leaves for “good reason”), severance is $67,500.
• Other facts: Contractor Agreement includes customary confidentiality provisions; no family relationships or reportable transactions requiring Item 404(a) disclosure.

Why It Matters

• Leadership change is material for investors because the CEO sets strategic direction and execution priorities. The filing confirms a planned transition (not a dispute) and provides concrete cost terms for the new CEO arrangement (contractor model, $350k annual fee, limited severance). Investors should note the contractor status (no employee benefits) and the Board’s ability to terminate the agreement at will, which affects potential retention risk and cash flow commitments. The written Contractor Agreement is filed as Exhibit 10.1 to the 8-K for those who want full terms.